Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.

International journal of molecular sciences - 14 Feb 2021

Hamada Shin, Matsumoto Ryotaro, Tanaka Yu, Taguchi Keiko, Yamamoto Masayuki, Masamune Atsushi

Abstract excerpt

Pancreatic cancer remains intractable owing to the lack of effective therapy for unresectable cases. Activating mutations of K-ras are frequently found in pancreatic cancers, but these have not yet been targeted by cancer therapies. The Keap1-Nrf2 system plays a crucial role in mediating the oxidative stress response, which also contributes to cancer progression. Nrf2 activation reprograms the metabolic profile...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malates
Share to Glutaminase
Share to Kelch-Like ECH-Associated Protein 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NF-E2-Related Factor 2

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Sulfides

Share to Thiadiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 33672789
DOI: 10.3390/ijms22041870
PMCID: PMC7918355

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nrf2 Activation Sensitizes K-Ras Mutant Pancreatic Cancer Cells to Glutaminase Inhibition.PMID 33672789Read ↗

Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.Semantic proximity Read ↗

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read ↗

Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.Semantic proximity Read ↗

Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma.Semantic proximity Read ↗

Molecular mechanisms and systemic targeting of NRF2 dysregulation in cancer.Semantic proximity Read ↗

Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levelsSemantic proximity Read ↗

The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen SpeciesSemantic proximity Read ↗

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerSemantic proximity Read ↗

KRAS G12D mutation eliminates reactive oxygen species through the Nrf2/CSE/H 2S axis and contributes to pancreatic cancer growth.Semantic proximity Read ↗

The Keap1–Nrf2 system in cancers: stress response and anabolic metabolismSemantic proximity Read ↗

KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?Semantic proximity Read ↗

Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.